Oxford Biomedica plc
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The… Read more
Oxford Biomedica plc (OXBDF) - Total Assets
Latest total assets as of June 2025: $216.32 Million USD
Based on the latest financial reports, Oxford Biomedica plc (OXBDF) holds total assets worth $216.32 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oxford Biomedica plc - Total Assets Trend (2013–2024)
This chart illustrates how Oxford Biomedica plc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oxford Biomedica plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Oxford Biomedica plc's total assets of $216.32 Million consist of 57.5% current assets and 42.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.2% |
| Accounts Receivable | $23.28 Million | 10.1% |
| Inventory | $13.57 Million | 5.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $29.22 Million | 12.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Oxford Biomedica plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oxford Biomedica plc's current assets represent 57.5% of total assets in 2024, an increase from 50.9% in 2013.
- Cash Position: Cash and equivalents constituted 26.2% of total assets in 2024, up from 15.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 19.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 12.6% of total assets.
Oxford Biomedica plc Competitors by Total Assets
Key competitors of Oxford Biomedica plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oxford Biomedica plc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Oxford Biomedica plc generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oxford Biomedica plc is currently not profitable relative to its asset base.
Oxford Biomedica plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.89 | 2.35 | 2.89 |
| Quick Ratio | 1.67 | 2.07 | 2.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $62.07 Million | $ 79.73 Million | $ 59.15 Million |
Oxford Biomedica plc - Advanced Valuation Insights
This section examines the relationship between Oxford Biomedica plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 30.75 |
| Latest Market Cap to Assets Ratio | 0.95 |
| Asset Growth Rate (YoY) | -8.2% |
| Total Assets | $231.64 Million |
| Market Capitalization | $220.17 Million USD |
Valuation Analysis
Near Book Valuation: The market values Oxford Biomedica plc's assets close to their book value ( 0.95x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Oxford Biomedica plc's assets decreased by 8.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oxford Biomedica plc (2013–2024)
The table below shows the annual total assets of Oxford Biomedica plc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $231.64 Million | -8.20% |
| 2023-12-31 | $252.34 Million | -45.16% |
| 2022-12-31 | $460.18 Million | +93.98% |
| 2021-12-31 | $237.23 Million | +28.98% |
| 2020-12-31 | $183.93 Million | +49.62% |
| 2019-12-31 | $122.93 Million | +9.37% |
| 2018-12-31 | $112.40 Million | +71.86% |
| 2017-12-31 | $65.40 Million | +14.86% |
| 2016-12-31 | $56.94 Million | +9.82% |
| 2015-12-31 | $51.85 Million | +53.38% |
| 2014-12-31 | $33.80 Million | +147.76% |
| 2013-12-31 | $13.64 Million | -- |